P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML

P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML

Bibliographic Details
Main Authors:	Jesse Tettero, Yara Buisman, Lok Lam Ngai, Costa Bachas, Bjorn Tore Gjertsen, Angèle Kelder, Arjan van de Loosdrecht, Markus Manz, Thomas Pabst, Willemijn Scholten, Gert Ossenkoppele, Jacqueline Cloos, David de Leeuw
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968700.12532.1d

Similar Items

Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
by: Jesse M. Tettero, et al.
Published: (2023-12-01)

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
by: Diana Hanekamp, et al.
Published: (2021-05-01)

MRD Tailored Therapy in AML: What We Have Learned So Far
by: Lok Lam Ngai, et al.
Published: (2021-01-01)

P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
by: Lok Lam Ngai, et al.
Published: (2023-08-01)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
by: Jesse Tettero, et al.
Published: (2023-08-01)

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
by: Jesse M. Tettero, et al.
Published: (2022-10-01)

Early response evaluation in AML using mass cytometry
by: Bjørn T. Gjertsen, et al.
Published: (2019-06-01)

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
by: Monique Terwijn, et al.
Published: (2014-01-01)

P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE
by: Hester van Zeeburg, et al.
Published: (2023-08-01)

Apheresis in Neurological Disorders
by: Johannes Dorst
Published: (2020-10-01)

P448: Withdrawn
Published: (2024-01-01)

The Evolving Treatment Landscape of AML
by: Sabine Blum, et al.
Published: (2022-03-01)

Therapeutic apheresis in autoimmune diseases
by: Bambauer R, et al.
Published: (2013-11-01)

Apheresis platelets in additive solution: Is it a good alternative to conventional group-specific apheresis platelets?
by: Amit Agrawal
Published: (2017-01-01)

EEE 448 - Sistem Komputer
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (1995)

Autologous Transplantation for Older Adults with AML
by: Beatrice U. Mueller, et al.
Published: (2018-09-01)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
by: Jacobien R. Hilberink, et al.
Published: (2023-06-01)

Apheresis in Autoimmune Encephalitis and Autoimmune Dementia
by: Rosa Rössling, et al.
Published: (2020-08-01)

Therapeutic apheresis in hematopoietic cell transplantation
by: Paul Höcker, et al.
Published: (2008-12-01)

Role of therapeutic apheresis in pediatric disorders
by: Rekha Hans, et al.
Published: (2016-10-01)

Leukocyte apheresis in the management of ulcerative colitis
by: Helmy Ahmed, et al.
Published: (2009-01-01)

Haematological Changes in Donors Post Apheresis
by: Nikhil, et al.
Published: (2021-07-01)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
by: Marte Karen Brattås, et al.
Published: (2018-11-01)

BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML
by: Ossenkoppele, G, et al.
Published: (2020)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
by: Muhammet Bulut, et al.
Published: (2020-01-01)

Gene expression profiles associated with pediatric relapsed AML.
by: Costa Bachas, et al.
Published: (2015-01-01)

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML
by: Anna Wojtuszkiewicz, et al.
Published: (2021-08-01)

Polyzwitterionic Coating of Porous Adsorbents for Therapeutic Apheresis
by: Vladislav Semak, et al.
Published: (2022-11-01)

LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
by: U. Julius, et al.
Published: (2018-09-01)

Therapeutic apheresis in kidney diseases: an updated review
by: Yi-Yuan Chen, et al.
Published: (2022-12-01)

Machine and man individualities in apheresis adverse events
by: Sudipta Sekhar Das, et al.
Published: (2018-01-01)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
by: Minichilli Fabrizio, et al.
Published: (2011-10-01)

Role of lipoprotein apheresis in the management of familial hypercholesterolemia
by: Shamanna Seshadri Iyengar, et al.
Published: (2021-01-01)

MKT 448 - Mekanik Bendalir November 1995
by: PPSM, Pusat Pengajian Sains Matematik
Published: (1995)

EEE 448 - SISTEM KOMPUTER APRIL 1995.
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (1995)

EEE 448 - SISTEM KOMPUTER APRIL 1997
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (1997)

VIII. Los años 434 a 448
by: Susan Bock
Published: (2019-07-01)

p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy
by: Ingvild Haaland, et al.
Published: (2021-04-01)

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
by: Jeroen Janssen, et al.
Published: (2021-02-01)

Thromboelastography as a tool for quality check of apheresis platelets
by: Anupam Verma, et al.
Published: (2016-01-01)